{"id":"NCT04340193","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer","officialTitle":"A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-14","primaryCompletion":"2023-12-12","completion":"2023-12-12","firstPosted":"2020-04-09","resultsPosted":"2024-11-26","lastUpdate":"2024-11-26"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cancer, Hepatocellular"],"interventions":[{"type":"DRUG","name":"nivolumab","otherNames":["Opdivo","BMS-936558"]},{"type":"DRUG","name":"ipilimumab","otherNames":["Yervoy"]},{"type":"PROCEDURE","name":"TACE","otherNames":[]}],"arms":[{"label":"Nivolumab + Ipilimumab + TACE","type":"EXPERIMENTAL"},{"label":"Nivolumab + TACE","type":"EXPERIMENTAL"},{"label":"TACE","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From first dose and 30 days after last dose of study therapy (up to approximately 25 months)","effectByArm":[{"arm":"NIVO+IPI+TACE","deltaMin":9,"sd":null},{"arm":"NIVO+TACE","deltaMin":9,"sd":null},{"arm":"TACE","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":107,"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","France","Germany","Hong Kong","Italy","Japan","Poland","Puerto Rico","Russia","Singapore","South Korea","Spain","Taiwan"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT04340193.html"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":9},"commonTop":["Pruritus","Constipation","Diarrhoea","Abdominal pain","Pyrexia"]}}